Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
For patients with obesity and elevated alk phos who have RA, do you check a fibroscan or serum NASH fibrosure test before starting methotrexate or leflunomide?
Related Questions
Does the presence of bronchiectasis change your approach to a patient with otherwise well-controlled patient with RA?
When do you recommend initiation of targeted therapies in active RA with history of malignancy?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
When considering biologic therapy after failure of MTX or triple therapy, do you consider using Abatacept as a first line biologic?
Would you uptitrate methotrexate dosing when a patient flares on a TNFi and methotrexate 15 mg weekly?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
What is your approach to work up for patients referred for early onset osteoarthritis?
How would you manage a patient with erosive seronegative rheumatoid arthritis with IgG and IgM deficiency?
Would you escalate therapy in a patient with rheumatoid arthritis without synovitis, but a new rheumatoid nodule?
How would you manage a patient with progressive/refractory molluscum contagiosum who is well controlled on methotrexate for seropositive rheumatoid arthritis?
